Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475393 | 1.00 | PSMB8 (0.70) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL2711265 | 0.84 | PSMB8 (0.75) | PSMB8PSMB5CA12CA1CA2 | |
| Benzene SCHEMBL28000606 | 0.82 | PSMB8 (0.72) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL30817868 | 0.82 | PSMB8 (1.00) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL329577 | 0.82 | PSMB8 (0.72) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL29164335 | 0.82 | PSMB8 (1.00) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL23626381 | 0.81 | PSMB8 (0.70) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL13851203 | 0.81 | PSMB8 (0.70) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL81178 | 0.81 | CA2 (1.00) | PSMB8PSMB5CA12CA1CA2 | |
| SCHEMBL10336550 | 0.81 | PSMB8 (0.70) | PSMB8PSMB5CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | claimed |
| US-5900427-A | N-heteroarenesulfonyl-protected amino acid reagents for peptide synthesis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-05-04 | — | — | US | claimed |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-114957053-B | Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof | 中国医学科学院医药生物技术研究所 | 2023-12-22 | — | — | CN | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116351341-A | Method for continuously preparing sulfonyl chloride compound by utilizing micro-reaction device | 盐城工学院 | 2023-06-30 | — | — | CN | disclosed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023094827-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-4551407-A | Transfer imaging system | THE MEAD CORPORATION (US) | 1985-11-05 | — | — | US | disclosed |
| US-4536463-A | Imaging system | THE MEAD CORPORATION (US) | 1985-08-20 | — | — | US | disclosed |
| US-4440846-A | Photocopy sheet employing encapsulated radiation sensitive composition and imaging process | MEAD CORPORATION (US) | 1984-04-03 | — | — | US | disclosed |
| US-4416966-A | Capsular imaging system comprising decolorizing agent | THE MEAD CORPORATION (US) | 1983-11-22 | — | — | US | disclosed |
| US-4399209-A | Transfer imaging system | THE MEAD CORPORATION (US) | 1983-08-16 | — | — | US | disclosed |
| US-RE29577-E | Anthraquinone dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | disclosed |
| US-4069259-A | Process for preparing organic disulfides | ALLIED CHEMICAL CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-3963763-A | Anthraquinone dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-15 | — | — | US | disclosed |
| US-3932419-A | QUINOLINE DYES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | PSMB8 1404/4885PSMB5 1135/4885CA12 1675/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | PSMB8 4523/4885PSMB5 4461/4885CA12 3915/4885 |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | PSMB8 3153/4885PSMB5 1955/4885CA12 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.